Precision BioSciences Q3 revenue falls sharply

Precision Biosciences

03/11/2025 12:10

Overview

Precision BioSciences Q3 revenue fell sharply

Net loss for Q3 widened compared to the same period last year

Company advances PBGENE-HBV and PBGENE-DMD programs with upcoming clinical milestones

Outlook

Company anticipates IND filing for PBGENE-DMD by end of 2025

Precision expects Phase 1 trial for PBGENE-DMD in 1H 2026

Company projects cash runway into 2H 2027 for clinical milestones

Result Drivers

PBGENE-DMD ADVANCEMENTS - Co highlighted preclinical data showing potential for PBGENE-DMD to restore dystrophin gene in DMD patients

COST REDUCTIONS - Co implemented operating efficiencies to reduce expenses and extend cash runway

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$13,000
Q3 Net Income
-$21.77 mln
Q3 Income from Operations
-$20.66 mln
Q3 Operating Expenses
$20.68 mln


Press Release: ID:nBw8T69PHa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)